Document Type : Research Articles
Authors
1
University of Central Punjab, Lahore, Pakistan.
2
Ghurki Trust Teaching Hospital, Lahore, Pakistan.
3
Department of Pharmacy, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
4
Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
5
Department of Pharmacy, Government College University Faisalabad, Lahore, Pakistan.
6
Basic Health Unit Mureedky, Lahore, Pakistan.
Abstract
Purpose: The purpose of this study was to address the question of “superiority of R-CHOP versus CHOP”, with
addition of Rituximab to CHOP, regarding survival of patients suffering from DLBCL. Patients and methods: A cohort
retrospective design was used to conduct this study in a tertiary care hospital. A total of 100 patients (50 in each group)
were randomly selected. The primary and secondary end points were EFS, OS, PFS and DFS. Kaplan Meier survival
curve analysis (log rank, Breslow and Tarone ware tests) was employed to compare probability of survival for the two
groups (CHOP/ R-CHOP). Results: The mean primary and secondary clinical indicators were estimated for each group
(EFS, 1.7; 3.09 with a p value P=0.02), (OS, 0.60; 0.43 with a p value P=0.40), (PFS, 1.73; 3.57 with a p value P=0.002), (DFS, 0.02; 0.48 with a p value of P=0.00). Conclusion:The results for differences in clinical response were statistically significant in favor of the R-CHOP group.
Keywords
Main Subjects
)